Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psychotherapeutic Medications Development Program (PMDP)

H J Haigler1, J M Cott, M V Rudorfer

  • 1National Institute of Mental Health, Rockville, MD 20857.

Psychopharmacology Bulletin
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early neuropsychological outcomes following pediatric acquired brain injury: a prospective longitudinal pilot study.

Applied neuropsychology. Child·2026
Same author

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

Schizophrenia research·2023
Same author

Corrigendum to "Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study" [Journal of Affective Disorders 138, 1-2 (2012): 86-95].

Journal of affective disorders·2019
Same author

Maternal anxiety, depression and sleep disorders before and during pregnancy, and preschool ADHD symptoms in the NINFEA birth cohort study.

Epidemiology and psychiatric sciences·2018
Same author

Bilateral Striatal Necrosis after Sydenham's Chorea in a 7-Year-Old Boy: A 2-Year Follow-Up.

Neuropediatrics·2018
Same author

Acute unilateral ophthalmoparesis associated with anti-GQ1b and GM1 antibodies after parvovirus infection in a 10-year-old girl.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2017

The National Institute of Mental Health's Psychotherapeutic Medications Development Program (PMDP) accelerates new mental illness drug development and enhances existing treatments. It focuses on drug discovery, technology transfer, and clinical evaluation to improve psychiatric medication accessibility.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Drug Development

Background:

  • The National Institute of Mental Health established the Psychotherapeutic Medications Development Program (PMDP) in 1990.
  • Mental illness treatment relies on effective and accessible psychotherapeutic medications.

Purpose of the Study:

  • To improve, enhance, and expedite the development of novel medications for mental illness.
  • To augment the therapeutic utility of currently available psychotherapeutic drugs.
  • To streamline the entire drug development pipeline from concept to regulatory approval.

Main Methods:

  • Implementing a four-initiative strategy: drug discovery and development, technology transfer, and clinical evaluation.
  • Facilitating the transfer of research from academic and government entities to the pharmaceutical industry.

Related Experiment Videos

  • Developing and maintaining capabilities for rigorous clinical evaluation of psychotherapeutic medications.

    • Main Results:

    • The PMDP actively supports the advancement of promising new drug candidates.
    • Efforts are directed towards enhancing the clinical effectiveness of existing psychotherapeutic medications.
    • The program aims to improve information dissemination and facilitate collaborations for technology transfer.

    Conclusions:

    • The PMDP plays a crucial role in advancing psychotherapeutic medication development.
    • The program's initiatives are designed to overcome barriers in bringing new treatments to patients.
    • Successful implementation is expected to lead to improved mental health treatment options.